Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes.


Options:
A: Arm Label: Arm I (CA for 4 courses); Type: ACTIVE_COMPARATOR; Interventions: Drug: AC regimen, Drug: doxorubicin hydrochloride | Arm Label: Arm II (CA for 6 courses [closed to accrual 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride | Arm Label: Arm III (paclitaxel for 4 courses); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Arm Label: Arm IV (paclitaxel for 6 courses [closed 12/15/2007]); Type: EXPERIMENTAL; Interventions: Drug: AC regimen, Drug: paclitaxel | Intervention Type: DRUG; Name: AC regimen; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]), Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007]) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (CA for 4 courses), Arm II (CA for 6 courses [closed to accrual 12/15/2007]) | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm III (paclitaxel for 4 courses), Arm IV (paclitaxel for 6 courses [closed 12/15/2007])
B: Arm Label: Arm A Taxane-containing; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Arm B standard anthracyclin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): Arm A Taxane-containing, Arm B standard anthracyclin
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: methotrexate, Drug: 5-fluorouracil | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: docetaxel | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): A
D: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A

Answer: D